Aminophylline for treating asthma and chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 2, Issue 3, 2008, Pages 305-313

  Nuhoglu, Yonca ^a,c   Nuhoglu, Cagatay ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Aminophyline; Asthma; COPD; Theophylline

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CIMETIDINE; CORTICOSTEROID; DILTIAZEM; ERYTHROMYCIN; GLUCOCORTICOID; HELIOX; ISONIAZID; ISOPRENALINE; MAGNESIUM SULFATE; METHYLXANTHINE; NIFEDIPINE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROPRANOLOL; RIFAMPICIN; ROXITHROMYCIN; SALBUTAMOL; STEROID; TERBUTALINE; THEOPHYLLINE; TROLEANDOMYCIN; UNINDEXED DRUG;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; BRONCHODILATING ACTIVITY; CHILD HEALTH CARE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIURESIS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INSOMNIA; INTENSIVE CARE; IRRITABILITY; LENGTH OF STAY; LOADING DRUG DOSE; LUNG FUNCTION; LYMPHOCYTE FUNCTION; MAINTENANCE THERAPY; NAUSEA; NEBULIZATION; OXYGEN SATURATION; PATHOGENESIS; PHARMACODYNAMICS; RESTLESSNESS; RISK REDUCTION; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; STANDARDIZATION; T LYMPHOCYTE; TREMOR; VOMITING;

EID: 46949096035     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.3.305     Document Type: Article

References (74)

1. Weinberger M, Hendeles L. Theophylline in asthma. N. Engl. J. Med. 334 (21), 1380-1388 (1996).
2. Ward AJ, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline: an immunomodulatory role in asthma? Am. Rev. Respir. Dis. 147(3), 518-523 (1993).
3. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med. 151(6), 1907-1914 (1995).
4. Kawai M, Kato M. Theophylline for the treatment of bronchial asthma: present status. Methods Find. Exp. Clin. Pharmacol. 22(5), 309-320 (2000).
5. Herrmann G, Aynesworth MB, Martin J. Successful treatment of persistent extreme dyspnea "status asthmaticus": use of theophylline ethylenediamine intravenously. J. Lab. Clin. Med. 23, 135-148 (1937).
6. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos C. Aminophylline improves diaphragmatic contractility. N. Engl. J. Med. 305(5), 249-252 (1981).
7. Kolbeck RC, Speir WA Jr, Carrier GO, Bransome ED Jr. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline. Lung 156(3), 173-183 (1979).
8. Higbee MD, Kumar M, Galant SP. Stimulation of the endogenous cathecolamine release by theophylline: a proposed additional mechanism of action for theophylline effects. J Allergy Clin. Immunol. 70(5), 377-382 (1982).
9. Horrobin DF, Manku MS, Franks DJ, Hamet P. Methyl xanthine phosphodiesterase inhibitors behave as prostoglandin antagonists in a perfused rat mesenteric artery preparation. Prostoglandins 13(1), 33-40 (1977).
10. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm. Pharmacol. 7(1), 1-17 (1994).
11. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl Acad. Sci. USA 99(13), 8921-8926 (2002).
12. Foukas LC, Daniele N, Ktori C et al. Direct effects of caffeine and theophylline on the p110d and other phosphoinositiode 3 kinases; differential effects on lipid kinase and protein kinase activities. J. Biol. Chem. 277(40), 37124-37130 (2002).
13. Fredholm BB. Theophylline actions on adenosine receptors. Eur. J. Respir. Dis. Suppl. 109, 29-36 (1980).
14. El-Hashim A, D'Agostino B, Matera MG, Page C. Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br. J. Pharmacol. 119(6), 1262-1268 (1996).
15. Bjorck T, Gustaffson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotriens and histamine. Am. Rev. Respir. Dis. 145(5), 1087-1091 (1992).
16. Cushley MJ, Tattersfield AE, Holgate ST. Adenosine-induced bronchoconstricition in asthma. Antagonism by inhaled theophylline. Am. Rev. Respir. Dis. 129(3), 380-384 (1984).
17. Mann JS, Holgate ST. Specific antagonism of adenosine-induced bronchoconstriciton in asthma by oral theophylline. Br. J. Clin. Pharmacol. 19(5), 685-692 (1985).
18. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets fbr anti-asthma drugs. Eur. Respir. 18(7), 1179-1183 (1995).
19. Markham A, Faulds D. Theophylline: a review of its potential steroid sparing effects in asthma. Drugs 56(6), 1081-1091 (1998).
20. Jaffar Z, Sullivan PJ, Page CP, Costello JF. Low dose theophylline therapy modulates T-lymphocyte activity in subjects with atopic asthma. Eur. Resp. J. 9(3), 456-463 (1996).
21. Shohat B, Volovitz B, Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin. Allergy 13(5), 487-493 (1983).
22. Fink G, Mittelman M, Sholat B, Spitzer SA. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin. Allergy 17(4), 313-316 (1987).
23. Page CP. Recent advances in our understanding of the use of theophylline in the treatmentof asthma. J. Clin. Pharmacol. 39(3), 237-240 (1999).
24. Finnerty JP Lee C, Wilson S, Madden J, Djukanovic R, Holgate ST. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo controlled paralld group study. Eur. Respir. J. 9(8), 1672-1677 (1996).
25. Ohta K, Sawamoto S, Nakajima M et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin. Exp. Allergy 26(Suppl. 2), 10-15 (1996).
26. Spoelstra FM, Berends C, Dijkhuizen B, de Monchy JG, Kauffman HF. Effect of theophylline on CD11b and L-selectin expression and density of cosinophils and neutrophils in vitro. Eur. Respir. J. 12(3), 585-591 (1998).
27. Mascali JJ, Cvietusa P, Negri J, Borish L. Antiinflammatory effects of theophylline: modulation of cytokine production. Ann. Allergy Asthma Immunol. 77(1), 34-38 (1996).
28. Punnonen J, de Wall Malefty R, van Vlasselaer P. IL-10 and viral IL-10 prevent IL-4 induced IgE synthesis by inhibiting the accessory cell function of monocytes. J. Immunol. 151(3), 1280-1289 (1993).
29. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction tolerance. J. Immunol. 151(5), 2390-2398 (1993).
30. Kroon LA. Drug interactions with smoking. Am. J. Health Syst. Pharm. 64(18), 1917-1921 (2007).
31. Mcelnay JC, Smith GD, Helling DK. A practical guide to interactions involving theophylline kinetics. Drug Intell. Clin. Pharm. 16(7-8), 533-542 (1982).
32. Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab. Dispos. 35(1), 79-85 (2007).
33. Weinberger MW, Matthay RA, Ginchansky EJ, Chidsey CA, Petty TL. Intravenous aminophylline dosage: use of serum theophylline measurement for guidance. JAMA 235(19), 2110-2113 (1976).
34. Zaske DE, Miller KW, Strem EL, Austrian S, Johnson PB. Oral aminophylline therapy: increased dosage requirements in children. JAMA 237(14), 1453-1455 (1977).
35. Ohnishi A, Kato M, Kojima J, Ushiama H, Yaneko M, Kawai H. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 20(1), 71-84 (2003).
36. Edgintou AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45(10), 1013-1034 (2006).
37. Cusack B, Kelly JG, Lavan J, Noel J, O'Malley K. Theophylline kinetics in relation to age: the importance of smoking. Br J Clin. Pharmacol. 10(2), 109-114 (1980).
38. Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin. Pharmacol. Ther. 24(4), 405-410 (1978).
39. Grygiel JJ, Birkett DJ. Cigarette smoking and theophylline clearence and metabolism. Clin. Pharmacol. Ther. 30(4),491-496 (1981).
40. Frye RF, Zgheib NK, Matzke GR et al. Liver disease selectively modulated cytochrome P-450-mediated metabolism. Clin. Pharmacol. Ther. 80(3), 235-245 (2006).
41. Mangione A, Imhoff TE, Lee RV, Shum LY, Jsko WJ. Pharmacokinetics of theophylline in hepatic disease. Chest 73(5), 616-622 (1978).
42. Self TH, Chafin CC, Soberman JE. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am. J. Med. Sci. 319(3), 177-182 (2000).
43. Vozeh S, Powell JR, Riegelman S, Costello JF, Sheiner LB, Hopewell PC. Changes in theophylline clearance during acute illness. JAMA 240(17), 1882-1884 (1979).
44. Itazawa T, Adachi Y, Nakabayashi M, Fuchizawa T, Murakami G, Miyawaki T. Theophylline metabolism in acute asthma with MxA-indicated viral infection. Pediatr. Int. 48, 54-57 (2006).
45. Odajima Y. Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children. Arerugi 41(1), 22-28 (1992).
46. Resar RK, Walson PD, Fritz WL, Perry DF, Barbee RA. Kinetics of theophylline variability and effect of arterial pH in chronic obstructive lung disease. Chest 76(1), 11-16 (1979).
47. Ohnishi A. A review of clinical use of theophylline in acute asthma: factors influencing kinetic disposition and drug interactions. Methods Find. Exp. Clin. Pharmacol. 22(4), 253-258 (2000).
48. Thomson NC. Asthma therapy: theophylline. Can. Respir. J. 5(Suppl. A), A60-A63 (1998).
49. Mitra A, Bassler D, Goodman K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst. Rev. (2), CD001276 (2005).
50. Jadad AR, Moore RA, Carroll D et al. Assessing die quality of randomized controlled trials: is blinding necessary? Control. Clin. Trials 17(1), 1-12 (1996).
51. Becker AB, Nelson NA, Simons ER. The pulmonary index assessment of a clinical score for asthma. Am. J. Dis. Child 138(6), 574-576 (1984).
52. Bien JP, Bloom MD, Evans RL, Specker B, O'Brien KP. Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled trial. Clin. Pediatr. (Phila.) 34(9), 475-481 (1995).
53. Carter E, Cruz M, Chesrown S, Shieh G, Reilly K, Hendeles L. Efficacy of intravenously administered theophylline in children hospitalised with severe asthma. J. Pediatr. 122(3), 470-476 (1993).
54. DiGiulio GA, Kercsmar CM, Krug SE, Alpert SE, Marx CM. Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. J. Pediatr. 122(3), 464-469 (1993).
55. Nuhoglu Y, Dai A, Barlan IB, Baaran MM. Efficacy of aminophylline in the treatment of acute asthma exacerbation in children. Ann. Allergy Asthma Immunol. 80(5), 395-398 (1998).
56. Strauss RE, Wertheim DL, Bonagura VR, Valacer DJ. Aminophylline therapy does not improve outcome and increases adverse even in children hospitalized with acute asthmatic exacerbations. Pediatrics 93(2), 205-210 (1994).
57. Wood DW, Downes JJ, Leeks HI. A clinical scoring system for the diagnosis of respiratory failure. Am J Dis. Child. 123(3), 227-228 (1972).
58. Yung M, South M. Randomized controlled trial of aminophylline for severe acute asthma. Arch. Dis. Child. 79(5), 405-410 (1998).
59. Bishop J, Carlin J, Nolan T. Evaluation of the properties and reliability of a clinical severity scale for acute asthma in children. J. Clin. Epidemiol. 45(1), 71-76 (1992).
60. Needleman JP, Kaifer MC, Nold JT, Shuster PE, Redding MM, Gladstein J. Theophylline does not shorten hospital stay for children admitted for asthma. Arch. Pediatr. Adolesc. Med. 149(2), 206-209 (1995).
61. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to β-2 agonists in adults with acute asthma. Cochrane Database Syst. Rev. (4), CD002742 (2000).
62. Siegel D, Sheppard D, Gelb A, Weinberg PE Aminophylline increases the toxicity but not the efficacy of an inhaled β-adrenergic agonist in the treatment of acute asthma exacerbations. Am. Rev. Respir. Dis. 132 (2), 283-286 (1985).
63. Emerman CL, Crafford WA, Vrobel TR. Ventricular arrhythmias during treatment for acute asthma. Ann. Emerg. Med. 15(6), 699-702 (1986).
64. Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann. Int. Med. 115 (4), 241-247 (1991).
65. Huang D, O'Brien RG, Harman E et al. Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? Ann. Int. Med. 119(12), 1155-1160 (1993).
66. Murphy DG, McDermott MF, Rydman RJ, Sloan ER Zalenski RJ. Aminophylline in the treatment of acute asthma when β-2 adrenergics and steroids are provided. Arch. Int. Med. 153(15), 1784-1788 (1993).
67. Coleridge J, Cameron P, Epstein J, Teichtahl H. Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. Aust. NZ J. Med. 23(4), 348-354 (1993).
68. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59(Suppl. 1), 1-232 (2004).
69. McKenzie DK, Frith PA, Burdon JG, Town GI; Australian Lung Foundation; Thoracic Society of Australia and New Zealand. The COPDX plan: Australian and New Zealand guidelines for the management of COPD 2003. Med. J. Aust. 178(Suppl.), S7-S39 (2003).
70. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 327(7416), 643-648 (2003).
71. Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 60(9), 713-717 (2005).
72. Chen CY, Yang KY, Lee YC, Perng PP. Effect of oral aminophylline on pulmonary function improvement and tolerability in different age groups of COPD patients. Chest 128(4), 2088-2092 (2005).
73. Inoue H, Yamauchi K, Kobayashi H, Tanifuji Y. The efficacy of intravenous theophylline injection for treatment of acute exacerbations of bronchial asthma. Arerugi 51(4), 379-382 (2002).
74. Yamauchi K, Kobayashi H, Tanifuji Y, Yoshida T, Pian HD, Inoue H. Efficacy and safety of intravenous theophylline administration for treatment of mild acute exacerbation of bronchial asthma. Respirology 10(4), 491-496 (2005).